NCT03387150View on ClinicalTrials.gov

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

December 7, 2020

Study Completion Date

December 7, 2020

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC07-523LS

Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

BIOLOGICAL

Placebo

Sodium Chloride for Injection USP, 0.9%; administered by IM injection

Trial Locations (7)

1011

Lausanne Vaccine and Immunotherapy Center CRS, Lausanne

27599

Chapel Hill CRS, Chapel Hill

35294

Alabama CRS, Birmingham

30308-2012

The Ponce de Leon Center CRS, Atlanta

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

02215-4302

Fenway Health (FH) CRS, Boston

10032-3732

Columbia P&S CRS, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03387150 - Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults | Biotech Hunter | Biotech Hunter